Milestone advances Clearmind’s clinical program as the company continues to develop CMND‑100 as a potential novel therapeutic candidate for alcohol use disorder Vancouver, Canada, Oct. 27, 2026 (GLOBE ...
Fintel on MSN
60 Degrees Pharmaceuticals, Inc. outlines tafenoquine clinical program for babesiosis and potential sNDA in 2027
60 Degrees Pharmaceuticals, Inc. updated its investor presentation on October 23, 2026, outlining the clinical development of tafenoquine for human babesiosis. The company is planning for a potential ...
BioStat.AI is built on the foundation of EDETEK's flagship platforms, CONFORM™ and eClinical, and leverages advanced AI technologies including large language models (LLMs), machine learning, and ...
Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder ...
The CTSC T32 grant-supported Clinical and Translational Scientist Training Program for Postdoctoral Researchers aims to develop Clinical/Translational scientists with skills for interdisciplinary work ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results